Published in FASEB J on February 02, 2010
Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica (2013) 1.32
Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol (2014) 1.04
Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood (2014) 1.03
The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm (2013) 1.01
Iron-deficiency anemia from matriptase-2 inactivation is dependent on the presence of functional Bmp6. Blood (2010) 0.97
Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation. PLoS One (2012) 0.91
Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. J Virol (2016) 0.83
Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method. Clin Chim Acta (2011) 0.82
Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events. Exp Hematol (2012) 0.82
Ferroportin and erythroid cells: an update. Adv Hematol (2010) 0.81
A tincture of hepcidin cures all: the potential for hepcidin therapeutics. J Clin Invest (2010) 0.78
Hepcidin in neoplastic disease. J Med Life (2013) 0.77
Huh-7 cell line as an alternative cultural model for the production of human like erythropoietin (EPO). J Transl Med (2011) 0.75
Oncostatin m modulation of lipid storage. Biology (Basel) (2015) 0.75
Regulation of the Iron Homeostatic Hormone Hepcidin. Adv Nutr (2017) 0.75
Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies. Front Immunol (2017) 0.75
The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest (2002) 7.90
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med (2002) 7.00
Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A (2002) 4.64
The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest (2003) 4.11
Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood (2008) 3.71
Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem (2003) 3.58
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest (2007) 3.40
AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J Clin Invest (2007) 3.32
Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes (2005) 2.88
HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest (2009) 2.47
Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet (2003) 2.41
On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. J Immunol (2002) 2.40
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood (2009) 2.38
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood (2013) 2.38
Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J (2005) 2.17
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell (2011) 2.12
Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem (2005) 2.04
Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood (2006) 2.04
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis (2003) 1.92
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene (2002) 1.87
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J Clin Invest (2005) 1.84
Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology (2006) 1.81
The alpha2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes (2004) 1.75
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 1.61
Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood (2004) 1.60
Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes (2004) 1.60
Role of AMPKalpha2 in basal, training-, and AICAR-induced GLUT4, hexokinase II, and mitochondrial protein expression in mouse muscle. Am J Physiol Endocrinol Metab (2006) 1.59
PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep (2012) 1.58
Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency? Br J Haematol (2011) 1.55
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica (2006) 1.54
A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem (2002) 1.49
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res (2010) 1.46
Inactive matriptase-2 mutants found in IRIDA patients still repress hepcidin in a transfection assay despite having lost their serine protease activity. Hum Mutat (2012) 1.46
Pathogenic T cells in cerebral malaria. Int J Parasitol (2006) 1.45
Functional differences between hepcidin 1 and 2 in transgenic mice. Blood (2003) 1.45
Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood (2002) 1.43
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood (2010) 1.38
In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood (2002) 1.37
Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes. Haematologica (2009) 1.36
Age-dependent retinal iron accumulation and degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci (2011) 1.32
Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood (2005) 1.31
A tamoxifen-inducible chimeric Cre recombinase specifically effective in the fetal and adult mouse liver. Hepatology (2002) 1.26
beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood (2007) 1.25
Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood (2010) 1.23
CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood (2003) 1.23
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica (2009) 1.21
Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes (2005) 1.21
Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood (2005) 1.20
Hepcidin, the iron watcher. Biochimie (2009) 1.19
Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood (2005) 1.18
Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica (2009) 1.17
Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics (2009) 1.14
Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice. J Immunol (2007) 1.14
Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol Cell Biol (2005) 1.14
Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica (2011) 1.13
Gab1, SHP-2 and other novel regulators of Ras: targets for anticancer drug discovery? Curr Cancer Drug Targets (2003) 1.12
Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr (2007) 1.10
Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus (2009) 1.09
Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nat Med (2011) 1.09
LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle (2011) 1.09
Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J (2003) 1.07
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica (2011) 1.07
Role of hepcidin in the setting of hypoferremia during acute inflammation. PLoS One (2013) 1.06
Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol Heart Circ Physiol (2006) 1.04
IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood (2010) 1.03
UV-induced expression of key component of the tanning process, the POMC and MC1R genes, is dependent on the p-38-activated upstream stimulating factor-1 (USF-1). J Biol Chem (2004) 1.02
Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract (2004) 1.01
Iron- and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo. Hepatology (2005) 1.01
Dual cardiac contractile effects of the alpha2-AMPK deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol (2007) 0.99
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood (2011) 0.98
AMP-activated protein kinase alpha2 deficiency affects cardiac cardiolipin homeostasis and mitochondrial function. Diabetes (2007) 0.97
Iron-deficiency anemia from matriptase-2 inactivation is dependent on the presence of functional Bmp6. Blood (2010) 0.97
The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions. Blood (2013) 0.96
Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced by Helicobacter pylori infection. Gut (2011) 0.96
Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle (2009) 0.95
Species-specific inhibition of cerebral malaria in mice coinfected with Plasmodium spp. Infect Immun (2005) 0.95
Hypoxia inhibits hepcidin expression in HuH7 hepatoma cells via decreased SMAD4 signaling. Am J Physiol Cell Physiol (2011) 0.95
Identification of proteins cleaved downstream of caspase activation in monocytes undergoing macrophage differentiation. J Biol Chem (2006) 0.95
The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood (2012) 0.92
Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood (2005) 0.92
Transcriptional regulation of adipocyte hormone-sensitive lipase by glucose. Diabetes (2002) 0.91
Hepcidin regulates intrarenal iron handling at the distal nephron. Kidney Int (2013) 0.90
Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process. J Hepatol (2008) 0.89